Zübeyde Nur ÖZKURT, Ferda CAN, Münci YAĞCI, Zeynep Arzu YEGİN, Sanem GÖKÇEN, Rezzan Eren SADİOĞLU, Çiğdem İLHAN

The Impact of Pre-transplant Cell-free DNA Levels on Leukemia Relapse and Transplant-related Complications in Allogeneic Hematopoietic Stem Cell Transplant Recipients

Background: Cell-free DNA, which may be considered as “liquid”biopsy, may serve as a diagnostic and prognostic marker not only inhematological malignancies but in solid tumors as well.Aims: To investigate the prognostic role of pre-transplant cell-freeDNA levels in allogeneic hematopoietic stem cell transplant recipients.Study Design: Retrospective cohort study.Methods: A total of 177 allogeneic hematopoietic stem cell transplantrecipients [median age: 36 (16-66) years; male/female: 111/66] withan initial diagnosis of acute leukemia were included in the study.Cell-free DNA was extracted from pre-transplant serum samples byusing the MagNA Pure Compact Nucleic Acid Isolation Kit I withthe MagNA Pure Compact instrument (Roche Diagnostics, Penzberg,Germany).Results: A positive correlation was demonstrated between cell-freeDNA and age (p=0.018; r=0.177). Pre-transplant cell-free DNAlevels were lower in bcr-abl (+) patients (p=0.001), while an adversecorrelation was indicated between cell-free DNA and bcr-abl levels(p=0.001; r=−0.531). Acute lymphoblastic leukemia patients withbcr-abl positivity (p=0.001) or abnormal cytogenetics (p=0.038)represented significantly lower pre-transplant cell-free DNA levels.Cell-free DNA levels were lower in patients who developed sinusoidalobstruction syndrome (p=0.035). In terms of long-term complications,acute myeloid leukemia patients who experienced post-transplantrelapse had significantly lower pre-transplant cell-free DNA levels(p=0.024). Overall survival was not statistically different betweenhigh- and low- cell-free DNA groups (45.2% vs 22.5; p=0.821).Conclusion: In general, low serum levels of pre-transplant çellfree DNA seem to be associated with transplant-related morbiditiesand may be considered an adverse prognostic factor for allogeneichematopoietic stem cell transplant recipients

PDF

___

1. Buedts L, Vandenberghe P. Circulating cell-free DNA in hematological malignancies. Haematologica 2016;101:997-9.
2. Hocking J, Mithraprabhu S, Kalff A, Spencer A. Liquid biopsies for liquid tumors: emerging potential of circulating free nucleic acid evaluation for the management of hematologic malignancies. Cancer Biol Med 2016;13:215-25.
3. Fettke H, Kwan EM, Azad AA. Cell-free DNA in cancer: current insights. Cell Oncol (Dordr) 2019;42:13-28.
4. Kubaczkova V, Vrabel D, Sedlarikova L, Besse L, Sevcikova S. Cell-free DNAMinimally invasive marker of hematological malignancies. Eur J Haematol 2017;99:291-9.
5. Kristensen LS, Hansen JW, Kristensen SS, Tholstrup D, Harsløf LB, Pedersen OB, et al. Aberrant methylation of cell-free circulating DNA in plasma predicts poor outcome in diffuse large B cell lymphoma. Clin Epigenetics 2016;8:95.
6. Kurtz DM, Scherer F, Jin MC, Soo J, Craig AFM, Esfahani MS, et al. Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma. J Clin Oncol 2018;36:2845-53.
7. Wu FT, Lu L, Xu W, Li JY. Circulating tumor DNA: clinical roles in diffuse large B cell lymphoma. Ann Hematol 2019;98:255-69.
8. Li M, Jia Y, Xu J, Cheng X, Xu C. Assessment of the circulating cell-free DNA marker association with diagnosis and prognostic prediction in patients with lymphoma: a single-center experience. Ann Hematol 2017;96:1343-51.
9. Martignano F. Cell-free DNA: An overview of sample types and isolation procedures. Methods Mol Biol 2019;1909:13-27.
10. Barták BK, Kalmár A, Galamb O, Wichmann B, Nagy ZB, Tulassay Z, et al. Blood collection and cell-Free DNA isolation methods influence the sensitivity of liquid biopsy analysis for colorectal cancer detection. Pathol Oncol Res 2019;25:915-23.
11. Dunaeva M, Buddingh’ BC, Toes RE, Luime JJ, Lubberts E, Pruijn GJ. Decreased serum cell-free DNA levels in rheumatoid arthritis. Auto Immun Highlights 2015;6:23-30.
12. Meddeb R, Dache ZAA, Thezenas S, Otandault A, Tanos R, Pastor B, et al. Quantifying circulating cell-free DNA in humans. Sci Rep 2019;9:5220.
13. Duvvuri B, Lood C. Cell-Free DNA as a biomarker in autoimmune rheumatic diseases. Front Immunol 2019;10:502.
14. Teo YV, Capri M, Morsiani C, Pizza G, Faria AMC, Franceschi C, et al. Cell-free DNA as a biomarker of aging. Aging Cell 2019;18:e12890.
15. Thijssen MA, Swinkels DW, Ruers TJ, de Kok JB. Difference between free circulating plasma and serum DNA in patients with colorectal liver metastases. Anticancer Res 2002;22:421-5.
16. Pérez-Barrios C, Nieto-Alcolado I, Torrente M, Jiménez-Sánchez C, Calvo V, Gutierrez-Sanz L, et al. Comparison of methods for circulating cell-free DNA isolation using blood from cancer patients: impact on biomarker testing. Transl Lung Cancer Res 2016;5:665-72.
17. Camus V, Sarafan-Vasseur N, Bohers E, Dubois S, Mareschal S, Bertrand P, et al. Digital PCR for quantification of recurrent and potentially actionable somatic mutations in circulating free DNA from patients with diffuse large B-cell lymphoma. Leuk Lymphoma 2016;57:2171-9.
18. Li M, Xu C. Circulating cell-free DNA utility for the surveillance of patients with treated diffuse large B-cell lymphoma. Clin Oncol (R Coll Radiol) 2017;29:637-8.
19. Alvarado-Vásquez N. Circulating cell-free mitochondrial DNA as the probable inducer of early endothelial dysfunction in the prediabetic patient. Exp Gerontol 2015;69:70-8.
20. Naumann DN, Hazeldine J, Dinsdale RJ, Bishop JR, Midwinter MJ, Harrison P, et al. Endotheliopathy is associated with higher levels of cell-free DNA following major trauma: A prospective observational study. PloS One 2017;12:e0189870.
21. Frank MO. Circulating cell-Free DNA differentiates severity of inflammation. Biol Res Nurs 2016;18:477-88.
22. Moreira VG, Prieto B, Rodríguez JS, Alvarez FV. Usefulness of cell-free plasma DNA, procalcitonin and C-reactive protein as markers of infection in febrile patients. Ann Clin Biochem 2010;47:253-8.
23. Pérez-Santiago J, Schrier RD, de Oliveira MF, Gianella S, Var SR, Day TR, et al. Cellfree mitochondrial DNA in CSF is associated with early viral rebound, inflammation, and severity of neurocognitive deficits in HIV infection. J Neurovirol 2016;22:191- 200.
24. Hohaus S, Giachelia M, Massini G, Mansueto G, Vannata B, Bozzoli V, et al. Cellfree circulating DNA in Hodgkin’s and non-Hodgkin’s lymphomas. Ann Oncol 2009;20:1408-13.
25. Manier S, Park J, Capelletti M, Bustoros M, Freeman SS, Ha G, et al. Whole-exome sequencing of cell-free DNA and circulating tumor cells in multiple myeloma. Nat Commun 2018;9:1691.
26. Oberle A, Brandt A, Voigtlaender M, Thiele B, Radloff J, Schulenkorf A, et al. Monitoring multiple myeloma by next-generation sequencing of V(D) J rearrangements from circulating myeloma cells and cell-free myeloma DNA. Haematologica 2017;102:1105-11.
27. Gao YJ, He YJ, Yang ZL, Shao HY, Zuo Y, Bai Y, et al. Increased integrity of circulating cell-free DNA in plasma of patients with acute leukemia. Clin Chem Lab Med 2010;48:1651-6.
28. Duque-Afonso J, Waterhouse M, Pfeifer D, Follo M, Duyster J, Bertz H, et al. Cellfree DNA characteristics and chimerism analysis in patients after allogeneic cell transplantation. Clin Biochem 2018;52:137-41.
29. Aljurf M, Abalkhail H, Alseraihy A, Mohamed SY, Ayas M, Alsharif F, et al. Chimerism analysis of cell-free DNA in patients treated with hematopoietic stem cell transplantation may predict early relapse in patients with hematologic malignancies. Biotechnol Res Int 2016;2016:8589270.
30. Herrera AF, Kim HT, Kong KA, Faham M, Sun H, Sohani AR, et al. Next-generation sequencing-based detection of circulating tumour DNA After allogeneic stem cell transplantation for lymphoma. Br J Haematol 2016;175:841-50.